1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 32; pp. S1172 - S1173
Main Authors Dowlati, A., Byers, L.A., Johnson, M.L., Aljumaily, R., Prenen, H., Zhang, A., Minocha, M., Shetty, A., Hashemi Sadraei, N.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2021
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.08.252